[HTML][HTML] Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
EA Akbay, J Kim - Translational lung cancer research, 2018 - ncbi.nlm.nih.gov
Lung cancer accounts for the greatest number of cancer deaths in the world. Tobacco smoke-
associated cancers constitute the majority of lung cancer cases but never-smoker cancers …
associated cancers constitute the majority of lung cancer cases but never-smoker cancers …
[HTML][HTML] ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?
M Patel, SK Jabbour, J Malhotra - Journal of Thoracic Disease, 2018 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018; 10 (Suppl 18): S2198-
S2201 jtd. amegroups. com 5-year follow up from the phase 1b, dose ranging CA209-003 …
S2201 jtd. amegroups. com 5-year follow up from the phase 1b, dose ranging CA209-003 …
[HTML][HTML] Ros1 fusion mediates immunogenicity by upregulation of pd-L1 after the activation of ros1–shp2 signaling pathway in non-small cell lung cancer
L Cai, J Duan, L Qian, Z Wang, S Wang, S Li… - Frontiers in …, 2020 - frontiersin.org
The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor
tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable. Whether …
tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable. Whether …
[HTML][HTML] From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on …
Y Zhou, F Wang, G Li, J Xu, J Zhang, E Gullen… - Frontiers in …, 2024 - frontiersin.org
Lung cancer is a disease of global concern, and immunotherapy has brought lung cancer
therapy to a new era. Besides promising effects in the clinical use of immune checkpoint …
therapy to a new era. Besides promising effects in the clinical use of immune checkpoint …
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
Background Despite recent advances in treating non‐small cell lung cancer (NSCLC) with
immune checkpoint inhibitors (ICIs), their role in ALK‐positive NSCLC patients is unclear …
immune checkpoint inhibitors (ICIs), their role in ALK‐positive NSCLC patients is unclear …
[HTML][HTML] Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
Y Cheng, H Li, L Zhang, JJ Liu, CL Yang… - Chinese Medical …, 2021 - journals.lww.com
In recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of
lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or …
lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or …
Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
D Sun, D Liu, Q Liu, H Hou - Cancer Biology & Therapy, 2020 - Taylor & Francis
Immune checkpoint inhibitors have demonstrated promising efficacy and tolerable safety for
advanced malignancies. However, a proportion of patients who had received …
advanced malignancies. However, a proportion of patients who had received …
[HTML][HTML] Current status and challenges of immunotherapy in ALK rearranged NSCLC
R Qi, Y Yu, M Shen, D Lv, S He - Frontiers in Oncology, 2022 - frontiersin.org
Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-
small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase …
small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase …
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 …
G Ruiz, D Enrico, YD Mahmoud, A Ruiz… - Thoracic …, 2024 - Wiley Online Library
Background Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive
biomarker of response to immune checkpoint blockade in non‐small cell lung cancer …
biomarker of response to immune checkpoint blockade in non‐small cell lung cancer …
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy
S Tabchi, HR Kourie, J Kattan - Investigational new drugs, 2016 - Springer
After the massive approval of checkpoint inhibitors in the treatment of numerous
malignancies and settings, checkpoint inhibitors-based combination therapies are emerging …
malignancies and settings, checkpoint inhibitors-based combination therapies are emerging …